Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 19, Issue 21, Pages 3858-3868Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/13816128113199990324
Keywords
Combined dyslipidemia; cholesterol; low-density lipoprotein-cholesterol; small; dense low-density lipoprotein; high-density lipoprotein-cholesterol; non-high-density lipoprotein-cholesterol
Categories
Funding
- Abbott
- Genzyme
- MSD
- Astra-Zeneca
- Bracco
- Chiesi Farmaceutici
- Novartis
- Novo-Nordisk
- Servier
- AMGEN
Ask authors/readers for more resources
As the population becomes more obese and the prevalence of diabetes and the metabolic syndrome increases, low-density lipoprotein-cholesterol (LDL-C) may lose its value as a sole predictor for cardiovascular risk among lipids. Combined dyslipidemia is typically characterized by elevations in LDL-C and triglyceride levels, often accompanied by decreased high-density lipoprotein-cholesterol (HDL-C) concentrations and increased levels of small, dense LDL. This common disorder results from overproduction of hepatically synthesized apolipoprotein B in very low-density lipoproteins. In the last few years most of the international scientific guidelines as well as several expert panels have confirmed that LDL-C represents the primary or even the only target of treatment. Yet, increasing evidence suggests moving away from a LDL-C target-based approach to a more tailored treatment approach. For example, non-HDL-C has been introduced in the last few years as a target of treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available